Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms
Annals of Hematology · 2023
DOI: 10.1007/s00277-023-05500-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2023. Verfasst von Xinhui Zheng und 16 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Hauptthemen laut MEDLINE: Neoplasms, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Myeloproliferative Disorders. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
This prospective clinical investigation focused on the addition of venetoclax and decitabine to myeloablative conditioning regimens, targeting high-risk and elderly individuals undergoing allogeneic hematopoietic stem cell transplantation. In total, 19 patients were enrolled in the trial between December 2021 and February 2023, and their progress was monitored for a median follow-up period of 258 days, ranging from 35 to 544 days. In the initial regimen (n=11), venetoclax was administered at a dosage of 400 mg per day from day -14 to day -1, while in the modified regimen (n=8), it was administered from day -14 to day -5. Decitabine was orally administered at a dosage of 20mg/m2/day from day -7 to day -3. Grade 3/4 adverse events observed included hematological events, hypertension, infections, allergy, and increased amylase. In the entire cohort, the overall survival (OS) and relapse-free survival (RFS) rates at 6 months were 63% (95% CI, 45-89) and 63% (95% CI, 45-89), respectively. The non-relapse mortality (NRM) rate at 6 months was 37% (95% CI, 16-58), while the cumulative incidence of relapse (CIR) was 0. However, the incidence of grade II-IV acute graft-versus-host disease (aGVHD) and grade III-IV aGVHD within 100 days was found to be 31% (95% CI, 12-53) and 26% (95% CI, 9-47), respectively. These rates indicate a relatively high occurrence, making it less suitable to administer the regimen to elderly patients. Therefore, further high-quality studies are required to enhance the conditioning regimen specifically for high-risk and elderly patients diagnosed with myeloid neoplasms. Clinical trial registration: ChiCTR2100050272.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
Zitieren
APA
Zheng, X., Gao, H., Lu, N., Wang, M., Zhang, H., Zheng, Y., Shen, B., Cao, Y., Chen, X., Zhai, W., Wei, J., Yang, D., Zhang, R., Pang, A., Feng, S., Jiang, E., & Han, M. (2023). Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms. Annals of Hematology. https://doi.org/10.1007/s00277-023-05500-2
Vancouver
Zheng X, Gao H, Lu N, Wang M, Zhang H, Zheng Y, et al. Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms. Annals of Hematology. 2023. doi:10.1007/s00277-023-05500-2
BibTeX
@article{Zheng2023,
author = {Zheng, Xinhui and Gao, Hongye and Lu, Ni and Wang, Mingyang and Zhang, Haixiao and Zheng, Yawei and Shen, Biao and Cao, Yigeng and Chen, Xin and Zhai, Weihua and Wei, Jialin and Yang, Donglin and Zhang, Rongli and Pang, Aiming and Feng, Sizhou and Jiang, Erlie and Han, Mingzhe},
title = {Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms},
journal = {Annals of Hematology},
year = {2023},
doi = {10.1007/s00277-023-05500-2}
}
EUVIMED